Former Peotone Firefighter Mike Shivers Recommended for Fire District Board Position
The Manhattan Fire Protection District board unanimously recommended Mike Shivers to fill a vacant trustee position left by the recent death of Trustee Bill Osborne.
Shivers, a former Peotone Fire Protection District board trustee who also served as a firefighter, was recommended during Monday’s board meeting as part of the district’s consolidation agreement to incorporate Peotone residents and board members.
“The agreement with the consolidation was to incorporate Peotone residents/Board members,” according to the meeting minutes. “Mike Shivers was a previous Peotone FPD Board Trustee and served as a Firefighter and is recommended to fill this vacant position.”
The recommendation passed on a unanimous roll call vote by the six current trustees: Bill Moncrief, Nick Kotchou (participating via Zoom), Larry Goodwin, Bill Weber, Bob Davis, and Brian Hupe.
The board appointment reflects the district’s commitment to maintaining representation from both Manhattan and Peotone communities following the consolidation of the two fire protection districts.
Osborne’s passing created the vacancy on the seven-member board, which oversees operations for the district serving both Manhattan and Peotone areas.
Latest News Stories
Illinois Quick Hits: Fuel price drops below $4.25, still higher than in 2025
California’s billionaire tax officially heads to Nov. 3 ballot
Los Angeles County on track to raise sales tax to 10.25%
EXCLUSIVE: Individual targeted in foiled UFC terror plot speaks out
Disability-rights advocates sue Illinois over physician-assisted suicide law
Supreme Court backs gun rights for marijuana users in 9-0 decision
Iran deal omits terror proxies, ballistic missiles, human rights
‘No kings’ at $830 million Obama Center opening
Alleged UFC White House ringleader was in US illegally
‘Policy blunder’ or ‘pathway to peace’: Republicans divided over Iran deal
Second produced water treatment pilot facility online in Permian Basin
Bill provides access to customized gene therapies, medicines